SC-2882 / Scenic Biotech - LARVOL DELTA

Qpctl Inhibition, By Targeting the Inflammatory Tumor Microenvironment, Constitutes a Novel Therapeutic Approach for Diffuse Large B-Cell Lymphoma (ASH 2023) - "SC-2882 is a first-in-class specific QPCTL inhibitor that induces secondary proteolytic degradation of the monocyte chemoattractants CCL2 and CCL7 (da Silva, Nature Immunology 2022) and inactivation of the "do-not-eat-me" signal CD47 (Logtenberg, Nature Medicine 2019)...Additional analysis of LME cell subpopulations by SC-RNA-seq is ongoing. Overall, these data indicate that QPCTL is a potential target in DLBCL, and that QPCTL inhibition exhibits potent anti-lymphoma effects primarily by targeting the IN-LME."

Biomarker • IO biomarker • Tumor microenvironment • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • CCL2 • CCL7 • CD47 • CD8 • EZH2 • FOXP3 • GLI2 • QPCT

SC-2882, a novel QPCTL inhibitor, with anti-tumor activity in solid tumor models (AACR 2024) - "SC-2882 is an orally administered small molecule inhibitor with a favorable PK profile. Preclinical studies show that SC-2882 was well tolerated in mice. In several mouse tumor models, SC-2882 reduced tumor growth in either single agent treated animals or in combination with anti-PD-L1 or cisplatin."

IO biomarker • Preclinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • CCL2 • CD47 • SIRPA

Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma (Businesswire) - "Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882....'Treatment with SC-2882 in a DLBCL mice model achieved a significant decrease in tumor growth and an increase of CD3+ T cell infiltration within the tumor microenvironment, along with a reduction in immunosuppressive immune cells. This suggests that QPCTL inhibition in DLBCL has anti-lymphoma effects and holds potential as a new therapeutic avenue for this type of cancer'..."

Preclinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology